SOLB Stock Analysis: Solvay | BR
Chemicals | BR, Belgium | Market Cap: 2.564m EUR | 12M Return: 4.4% | BE0003470755 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.75M
EPS Trend: -91.9%
Qual. Beats: 0
Rev. Trend: -83.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Solvay SA is a Belgian diversified chemicals producer that manufactures both basic (commodity) and performance (specialty) chemicals for global markets. The companys portfolio spans soda ash and bicarbonate, hydrogen peroxide, precipitated silica, polyamides, oxygenated solvents, and fluorine and rare-earth formulations, serving downstream industries including glass, lithium-ion batteries, detergents, pulp and paper, automotive tires, electronics, and food and feed.
As a diversified chemicals operator, Solvays business model combines high-volume inorganic commodities-where scale and access to low-cost raw materials are key-with specialty offerings whose margins depend more on technical differentiation and customer-specific applications. The company is headquartered in Brussels and traces its origins to 1863, making it one of the longer-established industrial chemical groups in Europe.
The companys end-market exposure links it to several long-term structural demand drivers, including energy transition (solar glass, EV batteries, photovoltaic chemicals), healthcare and food safety (bicarbonate, hydrogen peroxide), and mobility (tire silica, automotive electronics), while its commodity soda ash and peroxide businesses remain sensitive to industrial production cycles.
- Soda ash volumes rise on solar glass demand
- Silica sales grow with EV and tire demand
- European energy costs pressure commodity chemicals margins
| Net Income: 35.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.39 > 1.0 |
| NWC/Revenue: 8.27% < 20% (prev 13.11%; Δ -4.84% < -1%) |
| CFO/TA 0.08 > 3% & CFO 495.0m > Net Income 35.0m |
| Net Debt (2.22b) to EBITDA (647.0m): 3.43 < 3 |
| Current Ratio: 1.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.5m) vs 12m ago -0.03% < -2% |
| Gross Margin: 19.94% > 18% (prev 21.24%; Δ -1.30% > 0.5%) |
| Asset Turnover: 71.97% > 50% (prev 77.54%; Δ -5.57% > 0%) |
| Interest Coverage Ratio: 2.47 > 6 (EBIT TTM 286.0m / Interest Expense TTM 116.0m) |
| A: 0.06 (Total Current Assets 2.19b - Total Current Liabilities 1.82b) / Total Assets 6.21b |
| B: 0.24 (Retained Earnings 1.49b / Total Assets 6.21b) |
| C: 0.05 (EBIT TTM 286.0m / Avg Total Assets 6.27b) |
| D: 0.25 (Book Value of Equity 1.22b / Total Liabilities 4.93b) |
| Altman-Z'' = 1.74 = BBB |
| DSRI: 1.09 (Receivables 1.17b/1.17b, Revenue 4.51b/4.91b) |
| GMI: 1.07 (GM 21.24% / 19.94%) |
| AQI: 1.00 (AQ_t 0.28 / AQ_t-1 0.28) |
| SGI: 0.92 (Revenue 4.51b / 4.91b) |
| TATA: -0.07 (NI 35.0m - CFO 495.0m) / TA 6.21b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of November 08, 2026, the stock is trading at EUR 24.36 with a total of 557,205 shares traded. Over the past week, the price has changed by +2.27%, over one month by -2.01%, over three months by -8.83% and over the past year by +4.42%.
Current recommended Stop Loss: 23.60 (which is 3.1% or 1.4 ATR below the current price).
Solvay has no consensus analysts rating.
P/E Trailing = 74.3636
P/E Forward = 8.3963
P/S = 0.5682
P/B = 2.3455
P/EG = 0.2896
Revenue TTM = 4.51b EUR
EBIT TTM = 286.0m EUR
EBITDA TTM = 647.0m EUR
Long Term Debt = 1.84b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 401.0m EUR (from shortTermDebt, last quarter)
Debt = 2.59b EUR (from shortLongTermDebtTotal, last quarter) + Leases 379.0m
Net Debt = 2.22b EUR (calculated: Debt 2.59b - CCE 366.0m)
Enterprise Value = 4.79b EUR (2.56b + Debt 2.59b - CCE 366.0m)
Interest Coverage Ratio = 2.47 (Ebit TTM 286.0m / Interest Expense TTM 116.0m)
EV/FCF = 15.15x (Enterprise Value 4.79b / FCF TTM 316.0m)
FCF Yield = 6.60% (FCF TTM 316.0m / Enterprise Value 4.79b)
FCF Margin = 7.00% (FCF TTM 316.0m / Revenue TTM 4.51b)
Net Margin = 0.78% (Net Income TTM 35.0m / Revenue TTM 4.51b)
Gross Margin = 19.94% ((Revenue TTM 4.51b - Cost of Revenue TTM 3.61b) / Revenue TTM)
Gross Margin QoQ = 16.46% (prev 18.67%)
Tobins Q-Ratio = 0.77 (Enterprise Value 4.79b / Total Assets 6.21b)
Interest Expense / Debt = 4.48% (Interest Expense 116.0m / Debt 2.59b)
Taxrate = 20.93% (18.0m / 86.0m)
NOPAT = 226.1m (EBIT 286.0m * (1 - 20.93%))
Current Ratio = 1.21 (Total Current Assets 2.19b / Total Current Liabilities 1.82b)
Debt / Equity = 2.13 (Debt 2.59b / totalStockholderEquity, last quarter 1.22b)
Debt / EBITDA = 3.43 (Net Debt 2.22b / EBITDA 647.0m)
Debt / FCF = 7.03 (Net Debt 2.22b / FCF TTM 316.0m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.56% (Net Income 35.0m / Total Assets 6.21b)
RoE = 3.18% (Net Income TTM 35.0m / Total Stockholder Equity 1.10b)
RoCE = 9.74% (EBIT 286.0m / Capital Employed (Equity 1.10b + L.T.Debt 1.84b))
RoIC = 4.94% (NOPAT 226.1m / Invested Capital 4.57b)
WACC = 4.50% (E(2.56b)/V(5.15b) * Re(5.47%) + D(2.59b)/V(5.15b) * Rd(4.48%) * (1-Tc(0.21)))
Discount Rate = 5.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -43.34 | Cagr: -0.45%
[DCF] Terminal Value 76.25% ; FCFF base≈308.4m ; Y1≈326.1m ; Y5≈383.0m
[DCF] Fair Price = 35.15 (EV 5.89b - Net Debt 2.22b = Equity 3.67b / Shares 104.5m; r=8.35% [WACC [floored]]; 5y FCF grow 6.40% → 2.50% )
EPS Correlation: -91.94 | EPS CAGR: -42.39% | SUE: -0.81 | # QB: 0
Revenue Correlation: -83.39 | Revenue CAGR: -24.35% | SUE: 0.13 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.68 | Chg30d=+3.03% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=2.21 | Chg30d=-5.66% | Revisions=-58% | GrowthEPS=-22.2% | GrowthRev=-3.9%
EPS next Year (2027-12-31): EPS=2.36 | Chg30d=-6.38% | Revisions=-58% | GrowthEPS=+7.0% | GrowthRev=+2.4%
[Analyst] Revisions Ratio: -59% (up=3, down=16)